Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease
2 other identifiers
interventional
30
1 country
1
Brief Summary
Regular exercise reduces the risk of heart problems, in part because it improves the work of the endothelium (the cells that line blood vessels). Exercise appears to release precursor cells from the bone marrow that will later become endothelial cells. A molecule called nitric oxide (NO) appears to be involved in this release. However, some heart patients do not improve their endothelial function despite regular exercise. The researchers believe that the heart disease in these patients may interfere with the normal relationship between exercise and endothelial function. This study is designed to test whether giving a patient nitroglycerin (which is converted to NO in the bloodstream) will increase the release of endothelial precursor cells from the bone marrow. If the study succeeds, it may lead to improved healing of arteries in heart disease patients. Adults may be eligible for this study if they have coronary artery disease and do not take nitroglycerin or nitroglycerin-like medication on a daily basis. Volunteers will be admitted to the Clinical Center on 2 separate nights at least 1 week apart. On the morning after each admission, volunteers will have blood drawn from an arm vein for laboratory tests, and then walk on a treadmill until fatigue or discomfort prevents further exercise, or until asked to stop. On one of their admissions, volunteers will receive 1 tablet of nitroglycerin under the tongue shortly before the treadmill test. Volunteers will be monitored by EKGs and blood pressure tests during the treadmill tests, and will have more blood drawn at about 15 minutes and 24 hours after each treadmill test. Researchers will examine the levels of endothelial precursor cells and nitric oxide in the blood samples taken before and after exercise.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 coronary-artery-disease
Started Aug 2004
Shorter than P25 for phase_2 coronary-artery-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2004
CompletedFirst Submitted
Initial submission to the registry
August 27, 2004
CompletedFirst Posted
Study publicly available on registry
August 27, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2005
CompletedMarch 4, 2008
September 1, 2005
August 27, 2004
March 3, 2008
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Adults older than 21 years.
- Coronary artery disease established by angiography.
- No myocardial infarction within 1 month.
- Left ventricular ejection fraction greater than 30%.
- No congestive heart failure symptoms within 2 months.
- No associated medical, neurological or orthopedic condition that might prohibit safe performance of exercise.
- Subject understands protocol and provides written, informed consent in addition to willingness to comply with specified follow-up evaluations.
You may not qualify if:
- Significant structural heart disease (e.g. hypertrophic or dilated cardiomyopathy, valvular heart disease) as determined by echocardiography.
- History of recent (within 2 months) rest or nocturnal angina
- Organic nitrate (e.g., nitroglycerin) use other than study medication within 24 hours of exercise testing
- Hypersensitivity to organic nitrates.
- Women of childbearing age unless recent pregnancy test is negative.
- Lactating women.
- ELIGIBILITY CRITERIA - HEALTHY SUBJECTS
- Healthy subjects must be older than 50 years of age (to approximate the anticipated age of CAD patients), without known CAD, and be free of the following risk factors: blood pressure greater than 140/90 mmHg, fasting glucose greater than 110 mg/dL, smoking, total cholesterol greater than 250 mg/dL. Healthy subjects taking chronic prescription medications will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
August 27, 2004
First Posted
August 27, 2004
Study Start
August 1, 2004
Study Completion
September 1, 2005
Last Updated
March 4, 2008
Record last verified: 2005-09